In a study investigating the feasibility of using auranofin (Figure 1B) to treat non-small cell lung cancer (NSCLC), tumor cell death was observed in Calu3 and HCC366 cells treated with 0.5 μm auranofin for 24–48 h, possibly due to the inhibition of the PI3K/Akt signaling pathway (Li et al., 2016). The gene discussed is AKT1; the disease is neoplasm.